MersV1, Pmc, Checkpoint, bibRecord, 000A56

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Identifieur interne : 000A56 ( Pmc/Checkpoint ); précédent : 000A55; suivant : 000A57

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Auteurs : Jean-François Rossignol

Source :

Journal of Infection and Public Health [ 1876-0341 ] ; 2016.

RBID : PMC:7102735

Abstract

Summary

Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102735

DOI: 10.1016/j.jiph.2016.04.001
PubMed: 27095301
PubMed Central: 7102735

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 000E38
to stream Pmc, to step Curation: 000E38

Links to Exploration step

PMC:7102735

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</title>
<author><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">27095301</idno>
<idno type="pmc">7102735</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102735</idno>
<idno type="RBID">PMC:7102735</idno>
<idno type="doi">10.1016/j.jiph.2016.04.001</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000E38</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E38</idno>
<idno type="wicri:Area/Pmc/Curation">000E38</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E38</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000A56</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A56</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</title>
<author><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
</author>
</analytic>
<series><title level="j">Journal of Infection and Public Health</title>
<idno type="ISSN">1876-0341</idno>
<idno type="eISSN">1876-035X</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Summary</title>
<p>Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits <italic>in vitro</italic>
 activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include <italic>in vitro</italic>
 mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name>
</author>
<author><name sortKey="Azhar, E I" uniqKey="Azhar E">E.I. Azhar</name>
</author>
<author><name sortKey="Arabi, Y" uniqKey="Arabi Y">Y. Arabi</name>
</author>
<author><name sortKey="Alotaibi, B" uniqKey="Alotaibi B">B. Alotaibi</name>
</author>
<author><name sortKey="Rao, M" uniqKey="Rao M">M. Rao</name>
</author>
<author><name sortKey="Mccloskey, B" uniqKey="Mccloskey B">B. McCloskey</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
<author><name sortKey="La Frazia, S" uniqKey="La Frazia S">S. La Frazia</name>
</author>
<author><name sortKey="Chiappa, L" uniqKey="Chiappa L">L. Chiappa</name>
</author>
<author><name sortKey="Ciucci, A" uniqKey="Ciucci A">A. Ciucci</name>
</author>
<author><name sortKey="Santoro, M G" uniqKey="Santoro M">M.G. Santoro</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Belardo, G" uniqKey="Belardo G">G. Belardo</name>
</author>
<author><name sortKey="Cenciarelli, O" uniqKey="Cenciarelli O">O. Cenciarelli</name>
</author>
<author><name sortKey="La Frazia, S" uniqKey="La Frazia S">S. La Frazia</name>
</author>
<author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
<author><name sortKey="Santoro, M G" uniqKey="Santoro M">M.G. Santoro</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lam, K K Y" uniqKey="Lam K">K.K.Y. Lam</name>
</author>
<author><name sortKey="Zheng, X" uniqKey="Zheng X">X. Zheng</name>
</author>
<author><name sortKey="Forestieri, R" uniqKey="Forestieri R">R. Forestieri</name>
</author>
<author><name sortKey="Balgi, A D" uniqKey="Balgi A">A.D. Balgi</name>
</author>
<author><name sortKey="Nodwell, M" uniqKey="Nodwell M">M. Nodwell</name>
</author>
<author><name sortKey="Volett, S" uniqKey="Volett S">S. Volett</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Romark Laboratories" uniqKey="Romark Laboratories">Romark Laboratories</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Cao, J" uniqKey="Cao J">J. Cao</name>
</author>
<author><name sortKey="Forrest, J C" uniqKey="Forrest J">J.C. Forrest</name>
</author>
<author><name sortKey="Zhang, X" uniqKey="Zhang X">X. Zhang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Hong, S K" uniqKey="Hong S">S.K. Hong</name>
</author>
<author><name sortKey="Kim, H G" uniqKey="Kim H">H.G. Kim</name>
</author>
<author><name sortKey="Chong, C S" uniqKey="Chong C">C.S. Chong</name>
</author>
<author><name sortKey="Choi, I S" uniqKey="Choi I">I.S. Choi</name>
</author>
<author><name sortKey="Lee, J B" uniqKey="Lee J">J.B. Lee</name>
</author>
<author><name sortKey="Park, S Y" uniqKey="Park S">S.Y. Park</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Haffizulla, J" uniqKey="Haffizulla J">J. Haffizulla</name>
</author>
<author><name sortKey="Hartman, A" uniqKey="Hartman A">A. Hartman</name>
</author>
<author><name sortKey="Hoppers, M" uniqKey="Hoppers M">M. Hoppers</name>
</author>
<author><name sortKey="Resnick, H" uniqKey="Resnick H">H. Resnick</name>
</author>
<author><name sortKey="Samudrala, S" uniqKey="Samudrala S">S. Samudrala</name>
</author>
<author><name sortKey="Ginocchio, C" uniqKey="Ginocchio C">C. Ginocchio</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Public Health</journal-id>
<journal-id journal-id-type="iso-abbrev">J Infect Public Health</journal-id>
<journal-title-group><journal-title>Journal of Infection and Public Health</journal-title>
</journal-title-group>
<issn pub-type="ppub">1876-0341</issn>
<issn pub-type="epub">1876-035X</issn>
<publisher><publisher-name>Elsevier</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">27095301</article-id>
<article-id pub-id-type="pmc">7102735</article-id>
<article-id pub-id-type="publisher-id">S1876-0341(16)30018-1</article-id>
<article-id pub-id-type="doi">10.1016/j.jiph.2016.04.001</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</article-title>
</title-group>
<contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Rossignol</surname>
<given-names>Jean-François</given-names>
</name>
<email>jrossignol@romark.com</email>
<xref rid="cor0005" ref-type="corresp">⁎</xref>
</contrib>
</contrib-group>
<aff id="aff0005">Romark Laboratories, L.C., Tampa, FL, United States</aff>
<author-notes><corresp id="cor0005"><label>⁎</label>
Correspondence to: Romark Laboratories, L.C., 3000 Bayport Drive, Suite 200, Tampa, FL 33607, United States. <email>jrossignol@romark.com</email>
</corresp>
</author-notes>
<pub-date pub-type="pmc-release"><day>16</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
      <pub-date pub-type="ppub"><season>May-Jun</season>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub"><day>16</day>
<month>4</month>
<year>2016</year>
</pub-date>
<volume>9</volume>
<issue>3</issue>
<fpage>227</fpage>
<lpage>230</lpage>
<history><date date-type="received"><day>14</day>
<month>3</month>
<year>2016</year>
</date>
<date date-type="rev-recd"><day>21</day>
<month>3</month>
<year>2016</year>
</date>
<date date-type="accepted"><day>2</day>
<month>4</month>
<year>2016</year>
</date>
</history>
<permissions><copyright-statement>© 2016 King Saud Bin Abdulaziz University for Health Sciences. Production and hosting by Elsevier Limited.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>King Saud Bin Abdulaziz University for Health Sciences</copyright-holder>
<license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
</license>
</permissions>
<abstract id="abs0005"><title>Summary</title>
<p>Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits <italic>in vitro</italic>
 activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include <italic>in vitro</italic>
 mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals.</p>
</abstract>
<kwd-group id="kwd0005"><title>Keywords</title>
<kwd>Nitazoxanide</kwd>
<kwd>Coronavirus</kwd>
<kwd>MERS-CoV</kwd>
<kwd>Treatment</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A56 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000A56 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Pmc
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:7102735
   |texte=   Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i   -Sk "pubmed:27095301" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki